List of Diagnostics Companies in Canada - 44

AGADA Biosciences is a biotechnology company that specializes in providing expert assistance with drug development programs in neuromuscular disease, offering pre-clinical trials in mouse models and human clinical trial support.

ARC Medical Inc. is committed to improving the quality of life for people who have undergone surgery by developing safer and more effective innovative fluid medical devices that prevent the formation of surgical adhesions.

Our mission is to develop a portable, accurate, and convenient to use instrument for point-of-care testing of metabolite biomarkers. We are designing the instrument to be capable of non-invasive measurement of metabolite concentrations by scanning a finger. Powered by advances in Magnetic Resonance Spectroscopy (MRS), the instrument has universal detection capabilities that make it a compelling platform for improving clinical research, screening/diagnosis, and management of diabetes and other metabolic conditions.

We pursue promising science to address some of the toughest challenges in autoimmune disease. Community guidelines: 1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 2. Unless posts are from an official Aurinia social media handle, none of the posts or comments are posts made by us, but from members of the public. We take no responsibility for comments or posts made by third parties on our channels, and the content of those comments or posts (including any opinions or statements) may not reflect our views, and are the responsibility of the individual posting them. 3. We may discuss medical and health-related topics on our social media feeds. The content we post, and any associated content shared by other users, should not be taken as medical advice. We ask that you refrain from soliciting or posting medical advice on this feed. For advice and information related to your health, please seek advice from your doctor or other healthcare professional. 4. Aurinia reserves the right to remove any content or comments that violate these guidelines or are otherwise deemed inappropriate. We may block or ban users who repeatedly violate these guidelines or engage in disruptive behavior. To learn more, visit: https://www.auriniapharma.com/aurinia-community-guidelines US-NA-2300266 08/23

Cancer doesn’t wait — so we shouldn’t either. At Avitia, we’re making sure that clinical labs and oncologists everywhere have the tools they need to diagnose, as well as treat cancer faster. Our AI/ML technology ensures partners have cost-effective NGS-based molecular testing solutions that provide rapid turnaround times. Now, we empower healthcare teams to skip the delays and focus on what matters — personalized patient care. From pinpointing cancer mutations to streamlining clinical trial access, we’re here to make precision oncology accessible for every community and improve patients’ quality of life. Let’s transform cancer care together. Le cancer n’attend pas, et nous ne devrions pas non plus attendre. Chez Avitia, nous veillons à ce que les laboratoires cliniques et les oncologues du monde entier disposent des outils dont ils ont besoin pour diagnostiquer et traiter le cancer plus rapidement. Notre technologie IA/ML garantit à nos partenaires des solutions de tests moléculaires NGS rentables qui offrent des délais d’exécution rapides. Désormais, nous permettons aux équipes de soins de santé d’éviter les retards et de se concentrer sur ce qui compte : des soins personnalisés aux patients. De l’identification des mutations cancéreuses à la rationalisation de l’accès aux essais cliniques, nous sommes là pour rendre l’oncologie de précision accessible à toutes les communautés et améliorer la qualité de vie des patients. Transformons ensemble les soins contre le cancer.

BioMark is an oncology-focused company with advanced near-to- market diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites. We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory ,clinical and scientific standards.. Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.

BioNxt Solutions is a leading bioscience company that rapidly innovates drug formulations, diagnostics, drug delivery, and neurological drugs.

Bio-Test Laboratory strives to provide excellence in laboratory diagnostic services to patients and physicians.

Breathe BioMedical® is developing an innovative breath analytics platform to enable the early detection of disease. Our proprietary breath analytics technology is designed to collect, process and analyze breath samples to identify biomarker patterns associated with specific diseases. Breathe BioMedical is focused first on implementing a new breath test for breast cancer detection for women with dense breast tissue, as an adjunct to mammography, with the goal of increasing the number of breast cancer cases identified at the earliest stages. One day, detecting disease may be as easy as breathing.

CorVista Health is transforming cardiovascular care with the CorVista System, a non-invasive point-of-care diagnostic technology, that shortens the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. The CorVista System leverages proprietary machine-learned algorithms and robust clinical data to deliver results providers can trust. For more information visit www.corvista.com

Decipher Biosciences, formerly GenomeDx, is a genomic information company headquartered in Vancouver, British Columbia, with laboratories in San Diego, California.

We are Gemina Labs, a point-of-care test developer with a proprietary breakthrough chemistry platform. Founded in 2020, the Gemina chemistry platform is an advanced, “universal” bio-sensing toolkit that enables a new generation of diagnostic tests for infectious diseases and beyond. The chemistry platform isn’t just high-performing. It also overcomes many supply chain accuracy bottlenecks in the sector and cuts the development time for prototype tests to weeks. Best of all, the platform empowers “quantitative testing” (not just positive/negative tests) that opens up new applications in personal well-being (stress, fatigue monitoring etc.)

StageZero Life Sciences, Inc. is a national clinical reference lab specializing in personalized blood-based testing to find, understand, and provide key information to help guide treatment decisions. Our mission is to provide a comprehensive menu of traditional and advanced clinical evidence-based blood tests that aid in early cancer detection.

Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology, dedicated to the highest level of customer satisfaction, quality, and support, maintaining ISO 13485 medical device development and manufacturing standards certification. The Genomadix Cube is a real-time polymerase chain reaction (PCR) molecular diagnostic instrument capable of performing tests for precision medicine genotyping and environmental targets on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform includes tests for: - ​Rapid CYP2C19 Genotyping (FDA 510(k)-Cleared and CE Marked) - Environmental water testing for Legionella pneumophila - Apolipoprotein E (ApoE) RUO genotyping The Cube platform is also available as an open platform called CubeX that can be used to run any qPCR tests for research use only. Genomadix’s technology for the cube includes over 3 million hours of research and development, 11 patents and 30 peer-reviewed scientific publications.

Insight Medbotics is developing MRI-guided robotics to bring together the insights only MRI can provide with the minimally invasive access and precision of robotics. Our MRI-compatible robot, IGAR, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot inside an MRI, Insight Medbotics is now advancing the technology to improve the standard of care for prostate cancer. Our vision is to bring our advanced MRI-guided robotic technology to procedures where accuracy and precision matter most to patients, physicians and hospitals.

Improving healthcare through innovative technology is at the core of Intelerad’s work. Our scalable medical imaging platform connects clinicians to a powerful imaging ecosystem that is fast, smart and tapped into the data they need, no matter their location. We’re focused on delivering a best-in-class medical image management solution that improves provider efficiency, decreases the cost of healthcare, and improves the overall health of populations. For more information, visit www.intelerad.com. L'amélioration des soins de santé grâce à des technologies innovantes est au cœur du travail d’Intelerad. Notre plateforme d'imagerie médicale évolutive connecte les cliniciens à un écosystème d’images puissant, rapide et intelligent qui exploite les données dont ils ont besoin, peu importe leur emplacement. Nous concentrons nos efforts pour offrir la meilleure solution de gestion d'images médicales de l’industrie, qui augmente l'efficacité des fournisseurs, qui réduit le coût des soins de santé et qui améliore la santé globale des populations. Pour plus d'information, visitez www.intelerad.com/fr.

Laborie is a world-class specialist medical company that makes and advances technologies that preserve and restore human dignity. We take great pride in supporting doctors, nurses, hospitals, clinics, academic institutions and patients with treatment and diagnostic innovations. Our technologies include diagnostic equipment and consumable supplies in the Urology, Gastroenterology, Gynecology, Obstetrics and Neonatology fields. Privately owned by Patricia Industries and a part of the Investor AB network, Laborie is comprised of powerful brands that have been cultivated for more than 50 years. As a rapidly growing and scaling organization, our company values drive our day-to-day behaviors and make us ONE Laborie whenever and wherever we do business. We know that the work we do matters and we’re making a positive impact in the lives of patients across the globe. This is what fuels our motivation each day. If you’re ready to be part of a mission with meaning and a rewarding environment with opportunities for professional growth and career advancement, view our current job openings at https://laborie.bamboohr.com/jobs/ and apply online.

MedMira is transforming rapid testing with our patented Rapid Vertical Flow Technology™, offering speed, accuracy and multiplexing. This technology enables targets of interest in a wide variety of sample types to be captured and visualized on a unique membrane. Rapid Vertical Flow Technology is a highly scalable solution that can be used in the development and commercialization of rapid testing applications across a broad range of life sciences and biotech sectors. It’s rapid testing reinvented.

Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health and wellbeing. We manufacture a wide range of biological materials for the global diagnostics industry, notably antigens used in immunoassays and Quality Assessment Products (QAPs™). In 2021 we launched our first Viral Transport Medium, branded as DxTM. Microbix’s business of producing high-quality viral and bacterial preparations stems from over three decades of experience in the field, including strain selection, reliable and efficient organism culture at scale, purification, and pathogen inactivation. As a result of Microbix’s expertise, its products have received widespread and longstanding customer acceptance, with continuing growth in demand. Microbix’s current catalogue of biological preparations covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted, and insect-borne diseases. Microbix also applies its biological expertise to develop other innovative and proprietary technologies and products. Our development project pipeline currently includes Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots.

MolecuLight Inc. a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden > 10^4 CFU/g (when used with clinical signs and symptoms) and for digital wound measurement #moleculight

MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

Nanostics develops and commercializes novel, non-invasive diagnostic tests for cancer. Our core technology is an advanced liquid biopsy platform that can accurately diagnose cancer from a single drop of blood. Our lead product, ClarityDx Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer. Go to https://www.nanosticsdx.com/clarity-dx-prostate/ to order ClarityDX Prostate today.

ATGen Canada/NKMax Canada is the Canadian division of NKMax Co Ltd (Korea), a public biotechnology company dedicated to restoring and enhancing overall immune integrity. NK Vue, NKMax’s proprietary blood test for the measurement of immune function, is the first commercially available test that quantifies natural killer cell activity in a small volume of stimulated whole blood. NKMax also develops its proprietary natural killer cell expansion and activation technology as a treatment for a number of cancers and other disorders, and is currently conducting clinical trials in the US and Korea.

Norgen Biotek has been committed to customizing high-quality and innovative research tools to serve the scientific community for the past 25 years. Our mission is to provide the highest quality products and services to keep inspiring scientists to find new discoveries for the world. Subsequently, we focus on manufacturing sample collection, preservation, extraction, and detection products to enable our customers to achieve high throughput insights. We provide solutions to our customers in Life Sciences and Molecular Diagnostics. Furthermore, our products are distributed worldwide, and our technology has been featured thousands of times in peer-reviewed scientific publications by researchers from different institutions. Additionally, we have a team dedicated to providing Next Generation Sequencing Services with mastery in handling ultra-low concentration sample types, such as liquid biopsies and exosomes. At Norgen Biotek, we are #AlwaysReady to start long-lasting relationships and guarantee to meet customers' expectations. Working together, we can make the world better for all living beings. For more information, please visit norgebiotek.com.

Noze is the global leader in digital odor perception (often hailed as the digital equivalent of the sense of smell). We have developed the world's most advanced digital nose, capable of detecting and identifying odors in real-world settings with unparalleled accuracy. Leveraging cutting-edge machine intelligence and a sensor developed with exclusively licensed NASA technology, Noze is committed to enhancing human health and wellbeing. Our mission is to improve patient outcomes by enabling real-time disease detection at any point-of-care by using our technology to target breath-based odor biomarkers.

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

OPTITHERA was founded in 2016 and has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries. Based on these clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

pHLIP, Inc. was founded to bring its proprietary pHLIP® Platform Technology to the clinic, aiming to improve the treatment of diseases where visualization and targeted therapy would be highly advantageous. The possible applications of the technology are wide-ranging, including cancer, inflammation and fibrosis. Our dreams for the improvement of medicine include many possibilities: Imaging of the blood will allow the local circulation to be continuously monitored during surgery. Marking the surfaces of tumor cells will guide efficient and conservative removal of tumors or will activate the immune system to attack the tumor. Targeting of effective agents will alleviate inflammation. Targeted delivery of agents to cells in tumors will broaden the range of therapeutics while suppressing side effects.

Precision BioLogic develops, manufactures and markets innovative products for the clinical laboratory assessment of blood coagulation disorders. Precision's principal focus is in the field of hemostasis, for which the company has developed CRYOcheck, a line of specialized high-quality frozen plasmas, reagents and integrated test kits used in the assessment of hemostasis. Precision currently serves over 1,000 clinical laboratories throughout North America with direct overnight delivery and works with distribution partners to sell to customers overseas.

Pro-Lab Diagnostics is a privately held corporation founded in 1974. The head office is located in Ontario, Canada, with subsidiaries in the United Kingdom and the United States of America. Pro-Lab Diagnostics is registered under ISO 13585:2003 (CMDCAS) as well as with both the Therapeutic Products Directorate (TPD) of Health Canada and the Food and Drug Administration (FDA) of the United States. Pro-Lab's mission is to deliver today, and research for tomorrow. This is accomplished through extensive onsite research and development, leading to the manufacture of high quality and cost effective immunodiagnostic reagents. Additionally, Pro-Lab distributes a wide array of innovative products sourced from leading companies from around the globe. Disciplines covered include Clinical Microbiology, Molecular Biology, Transfusion Medicine, Instrumentation, Women's Health, Laboratory Ware, and much more. Pro-Lab also specializes in OEM (private label) packaging and welcomes new business opportunities. To find out more about Pro-Lab Diagnostics and its product offering, please visit our website at www.pro-lab.com.

ProMIS Neurosciences, Inc. is a leading development-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. The company is focused on the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy through the development of antibody therapeutics and diagnostics. ProMIS Neurosciences is publicly traded on the Toronto Stock Exchange.

ProMIS Neurosciences is focused on the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy through the discovery and development of antibodies selective for toxic misfolded proteins driving these diseases.

Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners have used our technologies to advance their R&D and drug discovery projects, and to publish papers in Nature Biotechnology, mAbs, and other journals.

Raspberry Scientific is committed to develop the future of molecular diagnostics with optical technologies to ensure faster, better and more affordable health care for all!

Response Biomedical Corp. develops, manufactures and markets the RAMP® system, a rapid diagnostics platform that delivers lab quality performance for efficient patient management in acute care settings. RAMP® is a global leader in comprehensive acute care testing with a wide range of markers available including Troponin I, CK-MB, Myoglobin, NT-proBNP, D-dimer and Procalcitonin. For effective and efficient patient care, RAMP® tests aid in the diagnosis of Acute Myocardial Infarction, Heart Failure and Sepsis.

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company for personalized cancer therapy management. We are working with physicians around the globe to improve cancer treatment and the quality of life for patients, while reducing healthcare costs. Our predictive biomarker platform technology, Veridapt DX™, now in clinical trials, is designed to measure early solid tumor response to neoadjuvant cancer treatment. The Veridapt DX predictive biomarker identifies non-responsive solid tumors by monitoring the degree of RNA (rRNA) disruption in the cells. Once validated, the test will enable physicians to escalate or de-escalate therapy, or select an alternative strategy, as early as 5 weeks into a standard 6-month treatment regimen. A series of pre-clinical studies, and retrospective and ongoing prospective clinical data, have shown strong evidence for clinical effectiveness. A large-scale study is now under way to validate Veridapt DX (formerly known as the RNA Disruption Assay) as a tool to manage primary breast cancer treatment: the Breast Cancer Response Evaluation for Individualized Therapy (BREVITY) clinical trial. Phase 1 results, published in JNCI Cancer Spectrum, demonstrate Veridapt DX’s strong capability (Negative Predictive Value >93%) to accurately predict therapy efficacy/outcomes during early treatment. Phase 2 is now under way in 7 countries. Our initial focus is on primary breast cancer; however, our assay platform has the potential to apply to any solid tumor and any cancer drug therapy for personalized, precision medicine. We welcome inquiries from clinicians interested in collaborative trials for early assessment of treatment for solid tumor cancers.

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

Syantra Inc. is a precision healthcare company changing the way cancer is detected and treated, starting with breast cancer. Learn about Syantra DX | Breast Cancer. A blood test for breast cancer screening that's easy, convenient and accurate.

Interested in working at Synex? Connect with us https://careers.synexmedical.com/ Our mission is to make predictive health a reality by providing accurate and non-invasive monitoring at the molecular level. Non-invasive glucose monitoring has been sought after for decades. Many people have tried. None have succeeded. Our novel approach to solving and going beyond this challenge will enable a future of true predictive healthcare. We’re looking for passionate and exceptionally talented people who want to be part of the team that achieves this vision.

SYNG Pharmaceuticals Inc. (SYNG Pharma) is a pre-clinical stage biotechnology company dedicated to developing next generation diagnostic and therapeutic against endometriosis. The company is developing a novel peptide, SP011, to inhibit a target now known for its role in the proliferation of cells. SYNG Pharma has a potential to develop a treatment that would be a much needed alternative to currently available, partly ineffective, hormonal therapy. There are many other potential applications of SYNG Pharma technology including the treatment of fibroids and uterine sarcoma; breast and prostate cancer which may be further developed depending upon corporate interests and an opportunity for partnership.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information about Telo Genomics please visit www.telodx.com.

uFluidix specializes in manufacturing silicone (PDMS) and thermoplastic (PMMA, PC, PS, COC, and COP) microfluidic chips and devices for microtechnology applications. Our expertise in the development and processing of these micro-featured components goes beyond the know-how of most of the plastic industry, who use conventional molding, stamping or rolling technologies. Our two differentiators are: 1. We affordably fabricate plastic parts with features accurate within +/- 0.5um if needed. 2. We bond or laminate hard-to-bond parts with less than 1% distortion of their sensitive micro-features. Over 10 years of experience has rewarded uFluidix with knowledge proven to be useful for a wide range of applications. If you are currently conceptualizing, improving, or validating an application from the list below we invite you to a friendly chat with one of our development specialists. We ensure you would hear something from us that is worth the experience. Applications: • Point-of-Care Blood/Urine Analysis Cartridges • Complicated Micro Arrays • Tissue Engineering Scaffolds • Customized Cell Culture Systems • Opto-electrical Methods • Point-of-Care Biomarker Detection • Pathogen Detection in Human/Animal • Optical-MEMS • Toxicity Measurements in Droplet Samples • Drug Efficacy Monitoring in Tiny Body Fluids • Cell Separation • Benchtop Cell Count Measurement • Fluidic Drug Delivery • Cancer Research via Biomarker or Cell Analysis • In-Vitro Platforms for Stem Cell Research • Selective Methods for Fertility Aid • Microfluidic Systems • Point-of-Care Sequencing Solutions • Portable Forensic Devices https://www.ufluidix.com/microfluidics-applications/ Any questions? Please visit ufluidix.com or email us at info@ufluidix.com

Yellowbird Diagnostics, Inc. specializes in biomedical imaging solutions across commonly used clinical imaging technologies. Our imaging solutions aim to empower physicians with actionable diagnostic information earlier in the onset of disease, seamlessly integrating into existing clinical workflows. Our product offerings consist of chemical contrast agents that are tailored to provide molecular information, allowing physicians to identify disease hallmarks before major anatomical changes occur due to inflammation, cancer, or other diseases.